Key statistics
On Thursday, Inhibikase Therapeutics Inc (IKT:NAQ) closed at 2.01, 151.85% above the 52 week low of 0.7981 set on Nov 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.98 |
---|---|
High | 2.03 |
Low | 1.75 |
Bid | 1.99 |
Offer | 2.10 |
Previous close | 1.98 |
Average volume | 416.22k |
---|---|
Shares outstanding | 67.19m |
Free float | 58.49m |
P/E (TTM) | -- |
Market cap | 133.04m USD |
EPS (TTM) | -2.72 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
More ▼